Rejuvenated A Year Into Saunders’ Return To Helm, B+L Refreshing Blink, Lumify Lines

Brimonidine tartrate eye drops remain key sales driver among Canadian firm’s consumer health lines with 12% growth in the latest quarter. B+L expects pending launch of preservative-free line extension to sustain Lumify as a driver as generics of original formulation are approved.

• Source: Shutterstock

Any honeymoon expected for Brent Saunders at Bausch + Lomb, Corporation may or may not be over after a year at the helm, but the special period known as market exclusivity the firm’s Lumify OTC switch eye drops enjoyed in the US could be passing with the first generic copy approved.

The brimonidine tartrate 0

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business